101 results
424B3
UBX
Unity Biotechnology Inc
8 Dec 23
Prospectus supplement
4:39pm
(foselutoclax) or any future product candidates;
our expectations regarding the potential benefits, activity, effectiveness, and safety of our drug candidates
8-K
EX-10.1
2412d
13 Nov 23
UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds
7:00am
8-K
EX-99.1
ahd91f4h6cxe
27 Sep 23
UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
7:05am
8-K
EX-99.2
1g6 edsbbxabh8hq
24 Apr 23
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:05am
8-K
EX-99.1
zs94g7i20u iq83
24 Apr 23
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:05am
8-K
EX-99.1
n1ufj1hd5 ca
1 Nov 22
UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:00am
424B5
ns2srxr9jira6lw3p uf
25 Oct 22
Prospectus supplement for primary offering
9:39pm